Ranbaxy's woes add $900 million in costs for heart drug in US

February 2014
FRPT- FMCG Snapshot;2/23/2014, p21
Industry Profile
Industry Report
The article reports on Ranbaxy Laboratories Ltd.'s inability to manufacture and market copies of Novartis AG's heart drug Diovan due to the failure of its Indian factories to comply with U.S. inspections. Topics discussed include the Diovan patent's expiry in 2012, steps in the approval process for generic drugs, and a gap in U.S. patent law that has kept Diovan copies off the market. Ranbaxy's rights to make copies of the AstraZeneca drug Nexium and Roche Holding's Valcyte is also cited.


Related Articles

  • Novartis Posts Profit Gain as New Drugs Deliver.  // MondayMorning;4/29/2013, Vol. 21 Issue 16, p1 

    The article informs that profit of the biotechnology company Novartis AG for the first-quarter of 2013 increased by seven percent. According to the company, earnings excluding some costs increased to 3.25 billion U.S. dollars. Analysts predicted profit of 3.12 billion U.S. dollars. Novartis...

  • Ranbaxy to triple Malaysian drug manufacturing output.  // TCE: The Chemical Engineer;Sep2013, Issue 867, p16 

    The article reports on the plan of Indian generics firm Ranbaxy Laboratories to build a $35 million worth of drugs manufacturing facility in Malaysia to triple its production rate in the country.

  • ANTIDIABETIC AGENTS.  // Monthly Prescribing Reference;May2013, Vol. 29 Issue 5, p94 

    The article offers brief information about several antidiabetic agents including the Glyset from Pfizer Inc., the Starlix from Novartis AG and the Rlomet from Ranbaxy Laboratories Ltd.

  • Ranbaxy's woes add $900 million in costs for heart drug in US.  // FRPT- FMCG Snapshot;4/20/2014, p21 

    The article reports that the delayed entry of pharmaceutical company Ranbaxy Laboratories Ltd. to manufacture and market copies of the heart drug Diovan manufactured by drug maker Novartis AG, due to a gap in U.S. patent law, has cost U.S. consumers and insurers as much as 900 million U.S....

  • SYMPTOMS OF FERMENT. SHARMA, E. KUMAR // Business Today;7/6/2014, Vol. 23 Issue 13, p70 

    The article reports on increasing mergers and acquisitions in pharmaceutical industry in India. It mentions the acquisition of Ranbaxy by Sun Pharma and realignment of business interest by Novartis AG and GlaxoSmithKline (GSK) Plc. It also presents the comments of Pharma sector expert Sanjiv...

  • GDUFA "Fix" Introduced in House.  // Contract Pharma;Jan/Feb2014, Vol. 16 Issue 1, p80 

    The article reports on the introduction of the Small Manufacturer Protection act 2013 (H.R. 3631) from Representatives Robert Hurt and Phil Roe, which is said to fix the drug manufacturing fees under the Generic Drug User Fee Act (ADUFA).

  • CHAIN PHARMACY: REPORTERS Notebook.  // Drug Store News;4/20/2009, Vol. 31 Issue 5, p92 

    The article offers news briefs related to pharmacy industry in the U.S. The Food and Drug Administration (FDA) approved the use of the drug manufactured by Eli Lilly and Co. for the treatment of severe depression. Daiichi Sankyo will let Ranbaxy, a company that it acquired in India, to promote...

  • Import alert issued.  // Contemporary Pediatrics;Oct2008, Vol. 25 Issue 10, p19 

    The article announces that the U.S. Food & Drug Administration (FDA) has issued a 2008 import alert for generic drugs produced by Ranbaxy Laboratories Limited's Dewas and Paonta Sahib plants in India, as well as two warning letters to Ranbaxy. According to the FDA, it detected deficiencies in...

  • FDA actions. Elliott, William T. // Clinical Oncology Alert;Nov2008 Pharmacology Watch, p2 

    The article reports that the U.S. Food & Drug Administration (FDA) has issued warning letters to Ranbaxy Laboratories Ltd. of India in an Import Alert for the company's generic drugs produced in two Indian plants. The warning letters identify concerns regarding deviations from U.S. current Good...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics